Back

Time to event analysis in patients managed on rivaroxaban while taking concurrent interacting medications (CIM)

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Antiplatelet and anticoagulant drugs Anticoagulants ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Jeffrey Michel

Baylor Scott and White Health, Austin (United States of America)

5 More presentations in this session

Presentation thumbnail
Aspirin resistance in patients with stable coronary heart disease
Doctor T. Petroni (Montauban, FR)
Abstract
Presentation thumbnail
CYP2C19-dependent clopidogrel resistance is a possible cause for coronary stent and peripheral bypass occlusion
Associate Professor M. Klinceva (Skopje, MK)
Abstract Slides
Presentation thumbnail
Fourier-spectroscopy capacity in assessment of resistance to acetylsalicylic acid in patients with stable angina pectoris
Mrs A. Kosinova (Elvas, PT)
Abstract Slides
Presentation thumbnail
Residual risk following myocardial infarction despite intensive medical management
Professor R. Rosenson (New York City, US)
Abstract Slides
Presentation thumbnail
Role of rivaroxaban in left ventricular thrombi
Doctor A. Almaghraby (Ras Al Khaimah, AE)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Antiplatelet and anticoagulant drugs

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
Direct oral anticoagulants or warfarin in patients with left ventricular thrombus: a meta-analysis of randomized clinical trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources